Gene | MET |
Variant | missense |
Amino Acid Change | V1110I |
Transcript ID (GRCh37/hg19) | ENST00000318493 |
Codon | 1110 |
Exon | 16 |
Germline/Somatic? | Somatic |
Tumor Type | Primary Site |
---|
Activating somatic mutations in the tyrosine kinase domain of MET are found in about 10-15% of sporadic papillary renal cell carcinoma (pRCC). MET mutations are predominantly associated with Type 1 pRCC tumors. The responses to foretanib an oral inhibitor of MET and other tyrosine kinases including VEGFR2, have been described in patients with papillary renal cell cancer.